Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMG 167
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
AMG 167 is an investigational biologic developed by Amgen for the treatment of osteopenia (low bone mineral density) in healthy men and postmenopausal women. It functions as a sclerostin (SOST) inhibitor, targeting the SOST protein to promote bone formation and increase bone mineral density. The drug has been evaluated in Phase 1 clinical trials (NCT01101048 and NCT00902356) to assess its safety, tolerability, and pharmacokinetics following subcutaneous administration. By inhibiting sclerostin, AMG 167 aims to counteract the natural suppression of bone formation, potentially offering a therapeutic approach for individuals with reduced bone mass.
02
Targets
SOST (Sclerostin)
Beyond the preview
Go deeper on AMG 167.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMG 167.